The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions

Reulen, Raoul C; Zeegers, Maurice P; Jenkinson, Crispin; Lancashire, Emma R; Winter, David L; Jenney, Meriel E; Hawkins, Mike M

doi:10.1186/1477-7525-4-77

Table 4 Correlation between scale scores and PCS/MCS scale scores.

From: The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions

	PCS								MCS
	PF	RP	BP	GH	EV	SF	RE	MH	PF	RP	BP	GH	EV	SF	RE	MH
UK norms [14]	0.79	0.75	0.78	0.64	0.38	0.51	0.11	0.13	0.05	0.26	0.20	0.42	0.73	0.65	0.78	0.89
Cancer Diagnosis
all survivors	0.85	0.82	0.73	0.60	0.40	0.62	0.27	0.13	0.13	0.27	0.32	0.53	0.76	0.59	0.73	0.91
leukaemia	0.83	0.81	0.69	0.55	0.33	0.63	0.28	0.13	0.14	0.24	0.36	0.59	0.80	0.57	0.68	0.90
Hodgkin's disease	0.83	0.81	0.72	0.55	0.34	0.61	0.20	0.16	0.09	0.27	0.37	0.55	0.78	0.60	0.77	0.89
non-Hodgkin's	0.85	0.77	0.78	0.70	0.40	0.54	0.25	0.13	0.13	0.29	0.25	0.40	0.78	0.65	0.79	0.92
CNS	0.88	0.82	0.67	0.66	0.47	0.67	0.32	0.11	0.10	0.28	0.37	0.48	0.71	0.54	0.70	0.91
neuroblastoma	0.81	0.80	0.71	0.50	0.32	0.55	0.20	0.07	0.04	0.31	0.45	0.62	0.78	0.67	0.75	0.88
retinoblastoma	0.83	0.83	0.75	0.54	0.31	0.50	0.28	0.05	0.16	0.21	0.26	0.55	0.80	0.64	0.75	0.92
Wilms' tumour	0.85	0.81	0.77	0.67	0.42	0.58	0.24	0.18	0.15	0.30	0.30	0.40	0.75	0.66	0.78	0.90
bone tumour	0.82	0.84	0.85	0.54	0.39	0.60	0.25	0.11	0.23	0.22	0.24	0.54	0.77	0.61	0.77	0.92
soft tissue sarcoma	0.85	0.80	0.78	0.67	0.44	0.52	0.19	0.14	0.11	0.27	0.28	0.44	0.70	0.68	0.81	0.90
other	0.83	0.77	0.80	0.61	0.45	0.60	0.25	0.16	0.17	0.34	0.24	0.52	0.73	0.61	0.78	0.90
Sex
Males	0.86	0.81	0.71	0.56	0.35	0.61	0.27	0.11	0.12	0.28	0.35	0.57	0.77	0.59	0.71	0.91
Females	0.85	0.82	0.75	0.63	0.43	0.63	0.27	0.12	0.14	0.27	0.29	0.49	0.75	0.59	0.75	0.91
Age*
16–19	0.84	0.82	0.55	0.47	0.28	0.62	0.27	0.10	0.11	0.25	0.49	0.62	0.82	0.58	0.67	0.89
20–29	0.86	0.80	0.71	0.59	0.40	0.59	0.22	0.14	0.10	0.28	0.30	0.52	0.75	0.61	0.76	0.91
30–39	0.85	0.81	0.75	0.57	0.36	0.62	0.27	0.13	0.15	0.28	0.30	0.54	0.78	0.60	0.73	0.90
40–49	0.85	0.84	0.76	0.69	0.44	0.68	0.37	0.14	0.19	0.26	0.31	0.46	0.74	0.56	0.70	0.92
50+	0.84	0.82	0.82	0.66	0.55	0.65	0.26	0.19	0.23	0.28	0.22	0.50	0.65	0.56	0.75	0.90
Age at diagnosis
0–3	0.85	0.82	0.71	0.59	0.36	0.62	0.31	0.11	0.11	0.28	0.36	0.53	0.79	0.59	0.71	0.91
4–7	0.86	0.82	0.69	0.60	0.41	0.65	0.24	0.13	0.11	0.24	0.35	0.53	0.74	0.57	0.74	0.90
8–11	0.87	0.80	0.75	0.59	0.40	0.58	0.27	0.12	0.13	0.31	0.30	0.53	0.75	0.61	0.74	0.91
12–16	0.84	0.82	0.79	0.59	0.40	0.61	0.24	0.13	0.18	0.26	0.26	0.54	0.76	0.61	0.76	0.91

*Age at questionnaire completion
PF: Physical Functioning; RP: Role-Limitation Physical; BP; Bodily Pain; GH: General Health Perception; EV: Energy/Vitality; SF: Social Functioning;
RE: Role-Limitation Emotional: MH: Mental Health

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us